Emerging Therapies for the Treatment of Tardive Dyskinesia

Emerging Therapies for the Treatment of Tardive Dyskinesia

On-Demand Webcast
Program Description

This activity was developed for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistances, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with tardive dyskinesia.

Tardive dyskinesia (TD), a syndrome characterized by hyperkinetic and abnormal involuntary movements, is common among patients treated with antipsychotics. TD imposes devastating effects on patient quality of life, negatively impacting daily function and social well-being. Symptoms are rarely reversible, with a cumulative risk incurred by the extent of antipsychotic treatment duration. This session will explore best practices for monitoring and preventing TD, as well as translate the evidence from clinical trial data to the timely treatment of TD.

Webcast Access

CLICK HERE to access the webcast and for complete accreditation information.

This activity is hosted on the Medscape website. Viewers will need to create an account before accessing the webcast. Please visit www.medscape.org or the above access link for more information.

Faculty

Rakesh Jain, MD, MPH (moderator) 
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine
Midland, Texas

Joseph P. McEvoy, MD 
Professor of Psychiatry & Health Behavior
I. Clark Case Chair in Psychotic Disorders
Medical College of Georgia
Augusta, Georgia

Christopher A. Ross, MD, PhD 
Professor of Psychiatry, Neurology, Neuroscience and Pharmacology
Johns Hopkins Medicine
Baltimore, Maryland 

Rajiv Tandon, MD 
Executive Vice Chair
Professor of Psychiatry
University of Florida
Gainesville, Florida 

Accreditation

In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hours.

Grant Support

This activity is supported by an educational grant from Teva Pharmaceuticals.